Navigation Links
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
Date:11/12/2007

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, November 14, 2007 at 8:30 A.M. EST to discuss the First Quarter fiscal 2008 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1-800-926-9907 (North America), 1-212-231-2913 (International).

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:TexSAn Heart Hospital Signs Agreement with Blue Cross and Blue Shield of Texas 2Health News:Indiana Blood Center Signs BIO-key(R) Contract 2Health News:Indiana Blood Center Signs BIO-key(R) Contract 3Health News:FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles 2Health News:FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles 3Health News:FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles 4Health News:Public Health Experts Argue for Integrated Services to Avert 7 Million HIV Infections by 2010 2Health News:America's 50 best hospitals 2008 released by HealthGrades 2Health News:America's 50 best hospitals 2008 released by HealthGrades 3Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 2Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 3Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 4Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 5
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Dynatronics Receives 180-Day NASDAQ Extension 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2Kevin Niksarli M D Of Newsight Laser Center New York N Y Reminds Early Detection Critical to Slowing Progress of Glaucoma on 6 17 2009 49538 1Kevin Niksarli M D Of Newsight Laser Center New York N Y Reminds Early Detection Critical to Slowing Progress of Glaucoma on 6 17 2009 49538 2RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 1RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 2RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 3RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 4Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its 24118 9 Million Convertible Notes Outstanding 49533 1Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its 24118 9 Million Convertible Notes Outstanding 49533 2Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its 24118 9 Million Convertible Notes Outstanding 49533 3